1-Cyclopentyl-2,2,2-trifluoroethan-1-amine hydrochloride | 1376380-74-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-Cyclopentyl-2,2,2-trifluoroethan-1-amine hydrochloride
• 英文别名: 1-cyclopentyl-2,2,2-trifluoroethanamine;hydrochloride
• CAS: 1376380-74-3
• 化学式: C7H13ClF3N
• mdl: MFCD22196522
• 分子量: 203.63
• InChiKey: KUXNOAUBDNRTEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-1-(oxetan-3-yl)-1H-indole-3-carboxylic acid 、 1-Cyclopentyl-2,2,2-trifluoroethan-1-amine hydrochloride 、 1,2-二氯乙烷 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 在 4-chloro-N-(1-cyclopentyl-2,2,2-trifluoroethyl)-1-(oxetan-3-yl)-1H-indole-3-carboxamide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以to obtain 4-chloro-N-(1-cyclopentyl-2,2,2-trifluoroethyl)-1-(oxetan-3-yl)-1H-indole-3-carboxamide (47, 17%)的产率得到4-chloro-N-(1-cyclopentyl-2,2,2-trifluoroethyl)-1-(oxetan-3-yl)-1H-indole-3-carboxamide
  参考文献：
  名称：

  NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES

  摘要：

  本发明涉及吲哚化合物及其药学上可接受的组合物，用作P2X7的拮抗剂，并用于治疗与P2X7相关的疾病。

  公开号：

  US20160168090A1

文献信息

• Indole derivatives and their use in neurodegenerative diseases
  申请人：Merck Patent GmbH

  公开号：US10323000B2

  公开（公告）日：2019-06-18

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及作为 P2X7 拮抗剂和用于治疗 P2X7 相关疾病的吲哚化合物及其药学上可接受的组合物。
• Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
  申请人：ARVINAS OPERATIONS, INC.

  公开号：US11173211B2

  公开（公告）日：2021-11-16

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；靶蛋白）的调节剂。特别是，本公开内容涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体，另一端含有与靶蛋白 RAF 结合的分子，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集或积聚或靶蛋白的组成性激活而导致的疾病或失调。
• INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：EP3233841A1

  公开（公告）日：2017-10-25
• POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：Arvinas Operations, Inc.

  公开号：EP3846907A1

  公开（公告）日：2021-07-14
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：ARVINAS OPERATIONS, INC.

  公开号：US20200129627A1

  公开（公告）日：2020-04-30

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.